Reports on chemical immobilization of proteins and enzymes first appeared in the 1960s. Since then, immobilized proteins and enzymes have been widely used in the processing of variety of products and increasingly used in the field of medicine.
INTRODUCTION
Reports on chemical immobilization of proteins and enzymes first appeared ∼30 years ago. Since then, immobilized proteins have been widely used for the processing of a variety of products spanning industries from food to environmental control. In addition to their use in processing, immobilized proteins and enzymes have also been found useful in many bioanalytical and biomedical applications. These applications include the use of immobilized antibodies or antigens in bioaffinity chromatography, of immobilized receptors or ligands in the study of their interactions, and of immobilized cells in biosensors. Although there have been a large number of articles discussing immobilization techniques of proteins and enzymes as well as their applications in certain fields, [1] [2] [3] a review on the applications of immobilized proteins and enzymes in medicine and particularly during the past decade (i.e., 1990s) is still lacking.
Presently, immobilized proteins/enzymes are used routinely in the medical field, such as in the diagnosis and treatment of various diseases. For example, immobilized antibodies, receptors, or enzymes are used in biosensors and ELISA for the detection of various bioactive substances in the diagnosis of disease states; encapsulated enzymes are also used in bioreactors for the removal of waste metabolites and correction of inborn metabolic deficiency. Moreover, the use of artificial cells as well as the development of controlledrelease drug delivery systems to release encapsulated enzymes or proteins may also be considered a form of immobilized enzyme use. However, this article will concentrate only on the review of current applications of traditionally defined immobilized enzymes in medicine; specifically in the areas of biosensors and bioreactors.
IMMOBILIZED ENZYME USED IN BIOSENSORS
Enzyme-based electrodes represent a major application of immobilized enzymes in medicine. The high specificity and reactivity of an enzyme towards its substrate are properties being exploited in biosensor technology. Biosensors possess advantages such as reliability, sensitivity, accuracy, ease of handling, and low-cost compared with conventional detection methods. These characteristics, in combination with the unique properties of an enzyme already mentioned, render an enzymebased biosensor ideal for biomedical applications. A summary of some recent applications of enzyme-based sensors in clinical diagnosis is presented in Table 1 . Our discussion on this subject will be classified into four different categories: enzyme immobilization, sensitivity and selectivity, optical biosensor, and implantable biosensor.
Enzyme Immobilization
An enzyme-based electrochemical sensor is formulated by immobilizing a thin layer of enzyme(s) on the surface of the membrane of an electrode. The analyte to be monitored diffuses into the enzyme layer where the catalytic reaction occurs, either consuming a substrate or generating a product that can be detected electrochemically. The electroactive species produced are monitored either potentiometrically or amperometrically, and the electrochemical signal can be correlated to the concentration of the analyte to be measured. The immobilization method may affect the activity of the immobilized enzyme, and thus it can contribute significantly to the sensitivity of the biosensor.
Immobilization methods that are currently being used include absorption, cross-linking, and self-assembly, whereas materials into which enzymes are incorporated include carbon paste, conducting or nonconducting polymers, and different types of gels. The ultimate aim of these efforts is to develop an inexpensive and easy-to-prepare method that can yield a stable matrix possessing the maximum retention of the biological activity of the immobilized enzyme. Generally speaking, physical entrapment of enzymes in polymeric membranes is one of the most advantageous methods because it is rapid and simple, the retained enzyme activity is usually quite high, plus no chemical reaction that may lead to the inactivation of the enzyme is required. The major limitation of physical entrapment is, however, that unlike chemical immobilization where all types of substrates, whether they are large or small, can all reach the immobilized enzyme for interaction, the physically entrapped enzyme is prohibited from interaction with large substrates that are unable to diffuse into the matrix. Therefore, for assaying a large substrate, chemically immobilized enzyme should be used.
In search of suitable matrices for enzyme immobilization, there has been a growing interest in attaching the enzymes to the solid electrolyte Nafion. The Nafion membrane possesses a high surface adhesion property and a low swelling capability in aqueous media. Being a negatively charged polyelectrolyte matrix, Nafion exhibits a reduced permeability to negatively charged substances, therefore improving the sensor selectivity and virtually eliminating the interference of reductants such as ascorbate and acetaminophen. On the other hand, a Nafion film possesses a high ability to entrap positively charged redox-active compounds that can be used as mediators in bioelectrocatalytic reactions. In addition, the polyelectrolyte nature of the Nafion film can stabilize the ionic strength at the electrode surface, thereby preventing electrode fouling and increasing the dynamic range for analyte detection. Other polymer films, such as poly(vinyl alcohol), 30 polytetrafluoroethylene, 31 poly(vinyl alcohol) grafted 4-vinylpyridine, 32 poly(pyrrole-ammonium)/ poly(pyrrole-lactobionamide), 33 polyaniline, 34 and poly(o-phenylenediamine) 35 have also been used recently in preparing biosensors because of their advantageous properties of high oxygen solubility, decent hydrophilicity, good biocompatibility, reasonable mechanical strength, and antifouling. 36 In addition, immobilization of heparin on artificial surfaces has also been extensively explored in an attempt to create a thromboresistant surface for the use of the biosensors in vivo. 37, 38 The low-temperature sol-gel process is another current attractive avenue for the immobilization of enzymes. Numerous sol-gel-based biosensors have been reported, and enzymes have been trapped in either inorganic or organic-modified inorganic materials such as silica, 39, 40 alumina, 41 silane, 42 and silver 43 matrixes. Compared with membranes made of other inorganic materials, such as clays 43 and zeolites 44 that limit enzyme immobilization because of their molecular dimensions, the porous organic or inorganic sol-gel matrix possesses physical rigidity, chemical inertness, high biodegradable property, and thermal stability. In addition, the sol-gel matrix yields insignificant swelling in both aqueous and organic solutions.
Sensitivity and Selectivity
Amperometric biosensors based on oxidase enzymes that generate hydrogen peroxide are the most widely used biosensors. Glucose determination utilizing the enzyme glucose oxidase (GOD) is an example of such an amperometric biosensor, and the principle of such glucose electrodes is based on the following reactions: 45 or to develop approaches that allow O 2 to be delivered externally to the electrode surface, thereby producing an excess level of O 2 (compared with that of glucose) at the electrode surface. 46 This excess amount of O 2 will allow for better regulation of the reaction environment and, hence, oxygen (instead of glucose) does not become the limiting reagent in the reaction. However, incorporation of catalase is undesirable for in vivo use of microelectrodes because a variation in the O 2 level in the surrounding medium may cause fluctuation in electrode response and thus a second electrode would be needed to measure the actual O 2 level so that the accurate concentration of the substrate can be determined. The main concern associated with the use of an external O 2 delivery system, on the other hand, is the difficulty in regulating the oxygen generation or supply, leading to possible introduction of an inadequate amount of oxygen to the electrode membrane. 46 Another approach to solve this oxygen deficiency problem is to place a diffusion-restriction membrane on top of the enzyme membrane. Such a diffusion-limiting membrane will yield high oxygen permeability but low glucose permeability, thereby providing a minimal concentration of glucose within the enzyme layer and a relatively constant amount of oxygen. [30] [31] [32] [33] [34] [35] Alternatively, some artificial electron acceptors or mediators, such as ferrocenes, 47 quinones, 48 diaminobenzenes, 49 and TTF, 50 have also been used to minimize the sensitivity to oxygen of the enzymebased electrodes. These electron-transfer mediators, which are retained at the electrode surface using a membrane or entrapped in an electrongenerated film at the surface, facilitate electron transfer between an electrode and a redox-active biological molecule, ensuring the attainment of a high signal-to-noise ratio. In addition to minimizing oxygen sensitivity, coupled mediated sensing systems, in which the mediator is attached to either the electrode or to the enzyme, could also provide a faster electron transfer, improved biosensor lifetime, 51 and reducing susceptibility to interferences from other electrochemically active species because of the low potential generally needed for oxidation of the mediators. 52 In addition, increased sensitivity and selectivity of a enzyme-based electrode can also be obtained by modifying the electrode surface with semiconducting films using electropolymerization of a redox monomer, such as phenazine, 53 phenoxazine and phenothiazine derivatives, 54 viologens, 55 and thionine. 56 Polymer-modified electrodes with a three-dimensional distribution of mediators are preferred over a monolayer distribution of mediators for the design of biosensors because a much larger catalytic response of the polymer coating will be obtained because of the volume effect. In general, the major obstacles that prevented rapid progress in the practical application of the semiconducting electrode in glucose sensing in the early of 1990s were: (1) physical instability and light sensitivity of the semiconductor structures; (2) dramatic decrease in the biosensor response to the change of buffer conditions and the ionic strength of the solution; and (3) limitation in the dynamic range of the biosensor response due to an insufficient concentration of dissolved oxygen in the measured samples. 57 However, with the advent of application of an additional semipermeable membrane on top of the enzyme layer and of enzyme field effect transistors, 58, 59 the stability, sensitivity, and dynamic range of semiconducting sensors have recently been greatly improved. 60 Because not all enzyme-catalyzed reactions are involved with transducer-active compounds (e.g., H + , O 2 , OH − ), only a limited number of substances can be determined by using a sensor consisting of a single enzyme. In this regard, the use of coupled enzyme reactions for analyte conversion provides a more favorable alternative. In such cases, the primary products produced by the reaction of the analyte with the first enzyme is further converted by a second enzyme to produce products detectable by a transducer. 61 Coupled enzyme reactions are also employed to filter out chemical signals by eliminating the interference on the enzyme and/ or tranducer reaction caused by other constituents in the sample. 62, 63 Alternatively, for certain measurements, an enzyme-based sensor can also be constructed by using the inhibition of the enzyme activity. In this case, the analyte is not a substrate but an inhibitor to the specific reaction of the enzyme. A reduction in the electrical signal can then be inversely correlated to the analyte concentration in the solution. 64, 65 Glucose dehydrogenase-based electrodes have also been developed to potentiometrically or amperometrically monitor glucose concentration. In most instances, glucose dehydrogenase systems require the presence of NAD or NADP. Requirements also depend on oxygen saturation of the sample and whether or not a redox mediator hasbeen incorporated 7, 8 to enhance glucose detection.
Optical Biosensor
In addition to the electrochemical transduction systems, interest in optical biosensors based on immobilized enzymes has also been gradually growing. Immobilization techniques used in optical sensors include adsorption, 66 physical entrapment, 67 and photocontrolled polymerization.
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The sol-gel method of entrapping enzymes in transparent silicate matrices is especially suitable in optical biosensors because it allows for the monitoring of chemical reactions of immobilized proteins by changes in the visible absorption spectra. 67 Fiberoptic biosensors for monitoring glucose, 69 cholesterol, 70 phospholipid, 71 and bilirubin 72 have been reported. Recently, the determination of analyte concentration is based on the measurement of the oxygen partial pressure in the analyte sample. In these devices, changes in the oxygen level were measured via quenching of the fluorescence of an oxygen-sensitive dye. In the case of the glucose sensor, the enzymatic depletion of oxygen, which is the result of transformation of the glucose by the immobilized enzyme glucose oxidase, leads to a decrease in the fluorescence quenching efficiency of the oxygensensitive dye element by O 2 ; as a result, the in-crease in the fluorescence intensity of the sensor during the enzymatic reaction corresponds to the glucose concentration. 69 Alternatively, H 2 O 2 produced in the oxidation of glucose by glucose oxidase can also be used for glucose detection through its further reaction with a dye precursor to produce a colored dye by the enzyme peroxidase. The rate of the colored dye formation is indicative of the glucose concentration. 73 The main drawback of this technology, however, lies in the rather slow response time for such fiberoptic biosensors, primarily because of the indirect nature for the analyte measurements. However, enzymes containing a flavin adeninedinucleotide (FAD) reaction site, such as glucose oxidase, cholesterol oxidase, and lactate monooxygenase, exhibit characteristic absorption spectrum with bands at 377 and 455 nm. On the addition of the analyte, the enzyme is almost completely decolorized; thus, the development of reagent-free sensor is also being explored. 67, 74 These sensors offer the advantage of more rapid communication with the optrode for response. Recently, FAD-or ferrocenereconstituted enzymes have been used in the enzymatic sensor and should offer some benefits in future development of the fiberoptic biosensing devices.
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Implantable Biosensor
Biosensors, in addition to the benefits of simplifying existing biochemical measurements, offer the advantage of allowing continuous and realtime monitoring. In addition to their main function in monitoring the rapid changes in blood analyte concentrations, biosensors provide an essential element to the development of artificial biofeedback systems that are useful in blood glucose control, drug dosing and administration, and intravenous infusion of nutrients. In general, devices in clinical use can be classified into three categories based on their size and site for applications: bedside units, wearable modules, and implantable devices. The bedside unit is a rather large and complex device containing a miniaturized sensor system used in the hospitals or intensive care units. Wearable modules can be attached to certain parts of the patient's body and are presently used in research for short-term monitoring of certain clinical entities. Implantable devices offer the convenience of being used as either a monitoring or an alarm device for continuous detection of certain substance levels in vivo. However, issues such as biocompatibility, generation of immune response to the sensor, long-term fouling of the electrode, and the need for frequent calibration still remain as major concerns for the successful application of implantable biosensors in vivo. The current trend in sensor development leans towards miniaturization and integration of the device. [77] [78] [79] [80] At the present time, enzyme-immobilized sensors capable of monitoring a variety of >10 different substances have already been commercialized, and a significant amount of effort is underway to further broaden the scope of applications.
IMMOBILIZED ENZYMES USED IN BIOREACTORS
The therapeutic application of immobilized enzyme in a bioreactor started as early as the 1960s. Since then, significant efforts have been made to apply this technology to the correction of inborn errors of metabolism, cancer treatment, blood detoxification, and removal of waste metabolites. Generally speaking, the enzyme(s) can be either immobilized on a solid support or encapsulated in sol-gel or an artificial cell (red blood cell or liposome) to construct the bioreactor. Although there are some reports on the immobilization of enzymes including phospholipase A 2 and heparinase [81] [82] [83] in bioreactors for blood detoxification, most efforts have been centered on the application of encapsulated enzymes for disease treatment. Compared with immobilized enzyme, enzymes entrapped in an artificial cell not only convert substrates that diffuse into the cell, but also possess low immunogenicity (due to the ability of artificial cells to mask their immune determinants) and prolonged blood clearance time. Initially, only a few enzymes, such as asparaginase and urease, had been used. Also, encapsulation of only single enzymes in the artificial cell had been attempted. At present, however, multiple enzymes are being encapsulated in one artificial cell, and such a multienzyme system has been used for the correction of metabolic imbalances. [84] [85] [86] [87] Recent examples of utilizing immobilized enzymes for clinical applications include artificial cells containing enzymes such as SOD, 88 asparaginase, 89, 90 urease, 91 lactate oxidase, 92 and alcohol oxidase 84, 87 for replacing hereditary enzyme deficiency, suppressing the growth of lymphosarcoma, decreasing systemic urea and lactate concentrations, and treating alcohol poisoning, respectively. Most recently, there is a tendency of utilizing cells that can self-express enzymes rather than encapsulating enzymes in the artificial cells. [93] [94] [95] Table 2 provides samples of bioreactors that have been extensively investigated during the last several years. Discussion of the most recent development in this field is classified into three categories: red blood cells as a carrier for enzymes, liposomes as a carrier for enzymes, and encapsulation of enzymes in sol-gel.
Red Blood Cell as A Carrier for Enzymes
As a new therapeutic approach, human and animal red blood cells (RBCs) have been used as the carrier vehicle for a number of exogenous enzyme drugs intended to be disseminated in an organism. 103 Because of their biocompatible nature, these cells will elicit little or virtually no immune response, thereby providing advantages of protecting the activity of encapsulated substances from rapid clearance and of avoiding toxic side effects. 104, 105 In addition, RBCs can be readily obtained, and a large quantity of the drug can be entrapped into a rather small volume of the cell using certain well-defined methods.
Techniques for induction of exogenous substances into RBCs include endocytosis, 106 passive diffusion, 107 electroporation, 84 and hypotonic dialysis/isotonic resealing, 108 etc. Among them, hypotonic dialysis/isotonic resealing is currently the most widely used technique because it is simple to use, it provides an efficient encapsulation of a large amount of the protein, it is adaptable for scale-up purposes, and it provides a carrier cell possessing the same in vivo half-life as that of the normal RBC. 109 Electroporation is another simple and efficient method for enzyme encapsulation. If the intensity of the electric field and the exposure time are maintained below certain critical values, the membrane rupture process required can be controlled to be completely reversible. Compared with hypotonic dialysis, electroporation provides several advantages, such as the preparation of the cell suspension can be achieved in an isotonic solution and the procedure can be manipulated easily and carried out routinely. 84 In addition to the loading techniques, the sources of RBCs can also affect the capacity for drug loading. Among different animal species from which the RBCs are obtained and treated with the hypotonic dialysis technique, the rat and rabbit have been reported to be the species that could present problems for enzyme encapsulation because these RBCs yield relatively low drug-loading capacity compared with human erythrocytes. 103, 110 Different methods employed in enzyme encapsulation could result in change in the properties of erythrocytes. A previous investigation has reported that erythrocytes to which the drug is loaded by the osmotic method function as the best drug carrier in systemic circulation because they are more stable than erythrocytes to which the drug is loaded by other methods. 111 On the other hand, chemically modified erythrocytes possess the benefit of targeting the organs of the mono- 
Liposome as a Carrier for Enzymes
Like RBCs, liposomes can also fulfill the promise of a drug-carrier vehicle because of their ability to reduce toxicity and enhance efficacy of the agents that are encapsulated. However, therapeutic application of liposomes administered by the intravenous route has been limited, primarily because of a rapid clearance of liposomes from the bloodstream and their uptake by the macrophage cells in the liver and spleen. 113 Recently, liposomes with the ability to evade the rapid uptake by the reticuloendothelial system (RES) have been developed, and a significant improvement in the blood half-life has been achieved by using liposomes whose surfaces are modified with polyethyleneglycol (PEG). 114, 115 The stabilization of the liposomes by PEG is due to the flexible dynamic motion of the PEG polymer chains that sterically prevent both electrostatic and hydrophobic interactions between the blood components and the liposome surface. 116 Because these liposomes exhibit dramatically different pharmacokinetics and biodistribution properties, 114, 115 they present a new avenue with regard to therapeutic applications. Recent applications of the PEG-modified liposomes include use in enhancing efficacy of antineoplastic agents against tumors, increasing delivery of antiinflammatory agents to the sites of inflammation, and targeting the extravascular system using such liposomes that are further linked with the targeting ligands.
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Encapsulation of Enzymes in Sol-Gel
Sol-gel is a chemical synthesis technology employed in preparing gels, glasses, and ceramic powders. Synthesis of materials by the sol-gel process generally involves the use of metal alkoxides, mostly but not exclusively the SiO 2 materials, which undergo hydrolysis and condensation polymerization reactions to produce the gel. It is now a well-established knowledge for a wide variety of enzymes and proteins that their reactivity and function can be fully retained when they are being confined within the pores of the sol-gel matrix. 118, 119 The porosity of the sol-gel glass allows small molecules to be diffused in, whereas the large enzyme macromolecule remains physically entrapped in the matrix. Sol-gel porous matrices in general, and doped matrices in particular, provide the following advantages: (1) they possess controllable surface area and relatively uniform pore size and distribution; (2) they are thermally stable; (3) they are able to enhance the stability of the encapsulated enzymes; and (4) they can prevent leaching of the entrapped enzyme. Recently, new classes of precursors, based on polyol silicates and polyol siloxanes and especially those derived from glycerol, have been under intense investigation. 120 These precursors can be distinguished from the traditional ones by properties such as being highly biocompatible and able to encapsulate proteins and cells under mild conditions in a reproducible manner. 120 Such characteristics enable the sol-gel carrier to address most of the problems encountered with traditional encapsulation methods. To this regard, like artificial cells, the sol-gel-entrapped enzymes may also be used in a bioreactor for the treatment of various enzyme-deficient diseases.
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CONCLUSION
This paper presents a brief review of recent (i.e., during the past decade) developments and medical applications of immobilized enzymes, particularly in the areas of biosensors and bioreactors. Although the progress in therapeutic use of immobilized enzymes is slow and somewhat staggered, because of the complexity of the human body system to be applied, the future prospect for application of immobilized enzymes in biosensing is promising. This promising future is particularly true because of the current advancement in technologies in microprocessing and microelectronic devices. Such technologies would allow the biosensors to be miniaturized during manufacturing, integrated with signal processing steps on a chip, and arrayed for more complicated substrate analysis. In addition, the progress in optical transducing devices provides another promising avenue that can be incorporated in biosensor development.
